The-11391 G/A Polymorphism of the Adiponectin Gene Promoter is Associated with Metabolic Syndrome Traits and the Outcome of an Energy-restricted Diet in Obese Subjects

TY - JOUR

T1 - The-11391 G/A Polymorphism of the Adiponectin Gene Promoter is Associated with Metabolic Syndrome Traits and the Outcome of an Energy-restricted Diet in Obese Subjects

AU - Coyenechea, E.

AU - Collins, L. J.

AU - Parra, D.

AU - Abete, I.

AU - Crujeiras, A. B.

AU - O'Dell, S. D.

AU - Martinez, J. A.

PY - 2009/1

Y1 - 2009/1

N2 - Adiponectin is an adipose tissue-specific hormone that is commonly decreased in obese Subjects. Furthermore, single-nucleotide polymorphisms (SNPs) of the adiponectin gene have been associated with metabolic phenotypes. The present Study investigated whether the adiponectin gene promoter variant - 11391 G/A (rs17300539) Could predict the risk of developing traits characterizing the metabolic syndrome (MetS) and the impact of weight management. The - 11391 G/A SNP was genotyped in 180 Spanish volunteers (BMI: 31.4 +/- 3.2 kg/m(2); age: 35 +/- 5 years). Clinical measurements were determined at baseline, following an 8-week low-calorie diet (LCD), and at 32 and 60 weeks. At baseline, the GG genotype was associated with higher HOMA-IR, insulin and triacylglyceride concentrations than other genotypes (p0.05). By 32 weeks after dietary therapy (n=84), GG carriers had recovered the risk of metabolic comorbidities (OR: 2.420, p=0.043). This risk was even more evident after 60 weeks (OR: 2.875, p=0.014). These data show an increased risk of insulin resistance and MetS complications in obese subjects of the - 11391 GG genotype. The risk was markedly reduced during an energy-restricted diet, but was not sustained. Carriage of the A allele therefore confers protection from weight regain, and the effect is particularly evident 32-60 weeks after the dietary intervention, when improvement in GG subjects had disappeared.

AB - Adiponectin is an adipose tissue-specific hormone that is commonly decreased in obese Subjects. Furthermore, single-nucleotide polymorphisms (SNPs) of the adiponectin gene have been associated with metabolic phenotypes. The present Study investigated whether the adiponectin gene promoter variant - 11391 G/A (rs17300539) Could predict the risk of developing traits characterizing the metabolic syndrome (MetS) and the impact of weight management. The - 11391 G/A SNP was genotyped in 180 Spanish volunteers (BMI: 31.4 +/- 3.2 kg/m(2); age: 35 +/- 5 years). Clinical measurements were determined at baseline, following an 8-week low-calorie diet (LCD), and at 32 and 60 weeks. At baseline, the GG genotype was associated with higher HOMA-IR, insulin and triacylglyceride concentrations than other genotypes (p0.05). By 32 weeks after dietary therapy (n=84), GG carriers had recovered the risk of metabolic comorbidities (OR: 2.420, p=0.043). This risk was even more evident after 60 weeks (OR: 2.875, p=0.014). These data show an increased risk of insulin resistance and MetS complications in obese subjects of the - 11391 GG genotype. The risk was markedly reduced during an energy-restricted diet, but was not sustained. Carriage of the A allele therefore confers protection from weight regain, and the effect is particularly evident 32-60 weeks after the dietary intervention, when improvement in GG subjects had disappeared.

U2 - 10.1055/s-0028-1087204

DO - 10.1055/s-0028-1087204

M3 - Article

SN - 1439-4286

VL - 41

SP - 55

EP - 61

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

IS - 1

ER -